肿瘤细胞治疗研究
英文原题：A bibliometric and visualized analysis of CAR-T or TCR-T in solid tumor (from 2015 to 2024).
A bibliometric and visualized analysis of CAR-T or TCR-T in solid tumor (from 2015 to 2024).
实体瘤占全部癌症的 90%，带来复杂微环境和耐药等挑战。
未标注：本篇文献计量分析考察了2015至2024年实体瘤中的CAR-T和TCR-T疗法。实体瘤占癌症的90%，其治疗面临微环境复杂和耐药等挑战。CAR-T和TCR-T疗法前景可观，但仍受抗原可及性和免疫抑制等问题制约。通过Web of Science，我们识别出989篇文章，发现研究数量显著增长，尤其是2023至2024年（年增长率39.9%）。美国和中国是主要贡献国家，并存在广泛国际合作。宾夕法尼亚大学和中山大学等机构是该领域的重要研究单位。共被引分析突出了O'Rourke等（Sci Transl Med 9(399):eaaa0984，2017；DOI:10.1126/scitranslmed.aaa0984）及Brown等（N Engl J Med 375(26):2561–2569，2016；原文所列DOI:10.1126/scitranslmed.aaa0984）的奠基性研究。新兴研究重点包括纳米颗粒、基因编辑和联合治疗。本研究凸显该领域的快速发展和全球协作，为未来研究方向提供参考。 补充信息：在线版本包含补充材料，网址为10.1007/s12672-026-04589-x。
UNLABELLED: This bibliometric analysis examines CAR-T and TCR-T therapies in solid tumors from 2015 to 2024. Solid tumors represent 90% of cancers, posing challenges like complex microenvironments and drug resistance. CAR-T and TCR-T therapies show promise but face issues such as antigen availability and immunosuppression. Using the Web of Science, we identified 989 articles, revealing a significant research increase, especially from 2023 to 2024 (an annual growth rate of 39.9% from 2023 to 2024). The United States and China were the leading contributors, with strong global collaborations. Key institutions included the University of Pennsylvania and Sun Yat-sen University. Co-citation analysis highlighted seminal works by O'Rourke et al. (Sci Transl Med 9(399):eaaa0984, 2017 10.1126/scitranslmed.aaa0984) and Brown et al. (N Engl J Med 375(26):2561 9, 2016 10.1126/scitranslmed.aaa0984). Emerging research foci included nanoparticles, gene editing, and combination therapies. This study underscores rapid progress and global cooperation in this field, providing insights for future research directions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at10.1007/s12672-026-04589-x.
MEMBER ACCOUNT
登录成功会直接打开下一页。
